Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "SMS-Pharmaceuticals-Limited"

13 News Found

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr
News | August 14, 2022

SMS Pharmaceuticals posts Q1FY23 consolidated loss at Rs. 12.76 Cr

The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.

SMS Pharmaceuticals receives approval for Ibuprofen by EDQM
Drug Approval | July 24, 2022

SMS Pharmaceuticals receives approval for Ibuprofen by EDQM

With this, the company can start selling Ibuprofen in the European markets.

SMS Pharmaceuticals revenue grows by 44%; Profit up 235%
News | August 10, 2021

SMS Pharmaceuticals revenue grows by 44%; Profit up 235%

This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times

Latest Stories

BMS’ Cobenfy sees steady start, eyes stronger growth ahead

Merck’s Capvaxive shows strong momentum amid industry vaccine decline

FDA rejects Regeneron’s Eylea HD pre-filled syringe application amid manufacturing setbacks

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Advances in genetic testing, fertility preservation, and ART are reshaping reproductive care across India: Dr. Umesh N Jindal, Director, Jindal IVF
Dr. Umesh N Jindal Director, Jindal IVF
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India

Packaging